Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | G6PD | P11413 | 1/20 | 0.37 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | GSR | P00390 | 1/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23958226 | 0.85 | RAD52 (0.45) | ALOX12RAD52KMT2AMDM2KDR | |
| SCHEMBL23958215 | 0.82 | MDM2 (0.49) | ALOX12RAD52KMT2AMDM2PSD | |
| SCHEMBL30103264 | 0.82 | MDM2 (0.49) | ALOX12RAD52KMT2AMDM2PSD | |
| SCHEMBL24110995 | 0.81 | ALOX12 (0.57) | ALOX12RAD52KMT2AMDM2G6PD | |
| SCHEMBL24111020 | 0.81 | ALOX12 (0.46) | ALOX12RAD52KMT2AMDM2CSF1R | |
| SCHEMBL23958227 | 0.81 | ALOX12 (0.46) | ALOX12RAD52KMT2AMDM2G6PD | |
| SCHEMBL24110973 | 0.80 | ALOX12 (0.47) | ALOX12RAD52KMT2AMDM2G6PD | |
| SCHEMBL23958355 | 0.80 | ALOX12 (0.46) | ALOX12RAD52KMT2AMDM2PSD | |
| SCHEMBL24111000 | 0.79 | ALOX12 (0.49) | ALOX12RAD52KMT2AMDM2G6PD | |
| SCHEMBL23958124 | 0.79 | MDM2 (0.51) | ALOX12MDM2G6PDPSDPDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-16 | — | — | US | disclosed |
| WO-2021215537-A1 | 2-HETEROARYLAMINOQUINAZOLINONE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | CRKL, CLIC4, CLIC1 | ALOX12 3240/4885RAD52 1428/4885KMT2A 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.